Terns Pharmaceuticals/$TERN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Terns Pharmaceuticals

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Ticker

$TERN
Sector
Health
Primary listing
NASDAQ

Employees

59
Headquarters
Foster City, United States
Website
www.ternspharma.com

TERN Metrics

BasicAdvanced
$713M
-
-$1.04
-0.06
-

What the Analysts think about TERN

Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.

Bulls say / Bears say

Terns initiated the dose-expansion portion of its Phase 1 CARDINAL trial for TERN-701 in 2L+ CML in April 2025 after completing dose escalation in under a year, demonstrating rapid operational execution and pipeline progress (GlobeNewswire).
New drug-drug interaction data from a healthy volunteer PK study show TERN-701 has no clinically relevant CYP3A4 or OATB1/3 inhibition versus asciminib, supporting safer co-administration with common medications and reinforcing differentiation in the allosteric TKI class (GlobeNewswire).
With cash and cash equivalents expected to provide runway into 2028, Terns is well-positioned to fund its lead programs—including TERN-701 and TERN-601—through key clinical milestones without near-term dilution (GlobeNewswire).
No pivotal major molecular response data for TERN-701’s Phase 1 CARDINAL study are expected until 4Q 2025, leaving investors exposed to extended clinical and regulatory risk without near-term efficacy readouts (GlobeNewswire).
Top-line 12-week weight-loss results for TERN-601 from the Phase 2 FALCON trial won’t be available until 4Q 2025, prolonging development timelines and heightening the risk of delays or interim setbacks (GlobeNewswire).
Novo Nordisk plans to launch an oral semaglutide obesity pill via telehealth platforms in early 2026, intensifying competition and potentially eroding market share for TERN-601 upon its eventual approval (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

TERN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TERN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TERN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs